France has accounted for a 3.9% share of the global clinical trials activity in 2021, registering a decrease when compared with the last ten-year average of a 5.1% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials in France
Industry sponsored trials held a 72.6% share of all the clinical trials in France in 2021, when compared with the ten-year average of 74.5%. Non-industry sponsored trials accounted for a 27.4% share in 2021 as against the average of 25.5% in the last ten years.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry sponsored clinical trials in France
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOncology was the leading therapy area for industry sponsored clinical trials in France in 2021 with a 40.5% share, as against a five-year average of 43.9% and a ten-year average of 41.7%.
Central Nervous System held a 9.5% share in 2021, over a five-year average of 10.3% and a ten-year average of 10.9%.
Immunology held a 7.3% share in 2021, compared to a five-year average of 7.1% and a ten-year average of 7.2%. Gastrointestinal held a 7.0% share in 2021, as against a five-year average of 6.8% and a ten-year average of 5.9%.
Infectious Disease held a 6.7% share, over a five-year average of 7.4% and a ten-year average of 8.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for non-industry sponsored clinical trials in France
Oncology was the leading therapy area for non-industry sponsored clinical trials in France in 2021 with a 28.5% share, as against a five-year average of 25.9% and a ten-year average of 30.2%.
Central Nervous System held a 22.3% share in 2021, over a five-year average of 20.3% and a ten-year average of 24.1%.
Infectious Disease held a 20.4% share in 2021, compared to a five-year average of 16.0% and a ten-year average of 14.4%. Cardiovascular held a 12.8% share in 2021, as against a five-year average of 12.3% and a ten-year average of 13.4%.
Metabolic Disorders held a 5.8% share, over a five-year average of 5.2% and a ten-year average of 5.6%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase III trials lead industry sponsored clinical trials in France in 2021
Phase III trials held a 43.0% share of industry sponsored clinical trials in France in 2021, over a five-year average of 42.3% and a ten-year average of 43.0%.
Phase II trials held a 41.7% share in 2021, as against a five-year average of 39.6% and a ten-year average of 37.7%. Phase IV trials held a 9.0% share in 2021, compared to a five-year average of 9.0% and a ten-year average of 10.0%.
Phase I trials held a 6.3% share in 2021, over a five-year average of 9.1% and a ten-year average of 9.4%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials lead non-industry sponsored clinical trials in France in 2021
Phase II trials held a 51.5% share of non-industry sponsored clinical trials in France in 2021, over a five-year average of 43.5% and a ten-year average of 43.2%.
Phase III trials held a 27.0% share in 2021, as against a five-year average of 29.2% and a ten-year average of 27.8%. Phase IV trials held a 19.3% share, compared to a five-year average of 24.0% and a ten-year average of 24.2%.
Phase I held a 2.2% share in 2021, over a five-year average of 3.3% and a ten-year average of 4.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
